Work

Mechanism of action of pimavanserin in Parkinson’s disease psychosis: targeting serotonin 5HT2A and 5HT2C receptors

Year: 2016
Type: article
Abstract: Pimavanserin, a novel agent approved for the treatment of Parkinson's disease psychosis, has potent actions as an antagonist/inverse agonist at serotonin 5HT2A receptors and less potent antagonist/inverse agonist actions at 5HT2C receptors.
Language: English
Field: Medicine
Open Access status: bronze
OpenAlex ID: W2515060406
FWCI: 3.667
Cites: 59
Cited by: 226
Related to: 10